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Purpose: To compare the effect of intravitreal aﬂibercept or ranibizumab drug type and frequency on visual
acuity outcomes in eyes with neovascular age-related macular degeneration (NVAMD) and early persistent retinal
ﬂuid after 3 initial monthly injections.
Design: A post hoc analysis of eyes enrolled in VIEW 1 and VIEW 2, 2 similarly designed, randomized, phase
3 trials.
Participants: A total of 1815 eyes with NVAMD from VIEW 1 and VIEW 2.
Methods: Analyses included patients with known ﬂuid status at baseline and weeks 4, 8, and 12 in 3
treatment groups: ranibizumab 0.5 mg every 4 weeks (Rq4) (n ¼ 595), intravitreal aﬂibercept injection (IAI) 2 mg
every 4 weeks (2q4) (n ¼ 613), and IAI 2 mg every 8 weeks (2q8) after 3 monthly injections (n ¼ 607).
Main Outcome Measures: Mean best-corrected visual acuity (BCVA) change from baseline over weeks 16
to 52 and the proportion of eyes that gained 15 letters or lost 5 letters were evaluated in eyes with and without
persistent ﬂuid (cystic intraretinal or subretinal ﬂuid at all 4 initial visits). Visual outcomes also were assessed in
eyes with persistent ﬂuid by ﬂuid type (intraretinal and subretinal ﬂuid).
Results: The proportions of eyes with persistent ﬂuid were 29.4%, 18.8%, and 20.3% in the Rq4, 2q4, and
2q8 groups, respectively. In these eyes, mean BCVA gain from baseline to week 52 was greater with 2q4
compared with Rq4 (P < 0.01) and 2q8 (P < 0.05), whereas it was similar with Rq4 and 2q8 (P ¼ 0.294). At week
52, similar proportions of eyes gained 15 letters (31.5%e35.2%), whereas fewer eyes lost 5 letters with 2q4
compared with Rq4 and 2q8 (6.5% vs. 16.6% and 16.2%). The pattern of visual outcomes was similar regardless
of ﬂuid type. In eyes without persistent ﬂuid, BCVA changes were similar across treatment groups.
Conclusions: In patients with early persistent ﬂuid, 2q4 may provide additional clinical beneﬁt over 2q8 or
Rq4. Ophthalmology 2016;123:1856-1864 ª 2016 by the American Academy of Ophthalmology. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Aﬂibercept is a soluble human fusion protein. It acts as a
decoy receptor for vascular endothelial growth factor
(VEGF) and placental growth factor, and has potent anti-
VEGF activity.1 In 2 pivotal phase 3 trials, VIEW 1 and
VIEW 2, in patients with neovascular age-related macular
degeneration (NVAMD), outcomes were similar for the
primary and secondary visual acuity end points when 2 mg
of intravitreal aﬂibercept injection (IAI) was given every 4
weeks (2q4) or every 8 weeks (2q8) after 3 initial monthly
injections, or when 0.5 mg ranibizumab was given every 4
weeks (Rq4) at week 52.2 These data led to an approval by
the United States Food and Drug Administration (FDA) in
2011 of IAI to treat NVAMD in the United States
monthly or every 2 months after 3 initial doses.
In VIEW 1 and VIEW 2, as well as the Comparison of
Age-related Macular Degeneration Treatment Trials
(CATT), there was a rapid reduction of macular ﬂuid, as
measured by optical coherence tomography (OCT), in the1856  2016 by the American Academy of Ophthalmology
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(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Incmajority of treated eyes during the ﬁrst several weeks of
therapy.2,3 However, a subgroup of eyes had residual ﬂuid
on OCT despite injections with anti-VEGF drugs.2,3 In the
CATT, at each study visit, eyes with residual intraretinal
ﬂuid had worse visual acuity than those without intraretinal
ﬂuid, whereas eyes with subretinal ﬂuid had better visual
acuity than eyes without ﬂuid in that location. These ﬁnd-
ings were particularly prominent when the ﬂuid affected the
fovea and were independent of drug or treatment regimen.4
In multiple randomized trials, on average, eyes that are
given ﬁxed-dosing anti-VEGF treatments had better visual
acuity at 1 and 2 years than those given less frequent
treatments.2,3,5e9 Furthermore, when patients were given
monthly treatment for 1 year and then switched to a pro re nata
(PRN) regimen, the visual acuity decreased to a level similar to
that of patients given PRN treatment all along.10 Despite these
ﬁndings, in the United States, the majority of patients with
NVAMD are given fewer than monthly intravitreal.
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or “treat-and-extend” strategy.11 Treatment decisions often are
driven by the presence of ﬂuid seen on OCT.11 However, the
factors that determine the needed anti-VEGF treatment fre-
quency in any individual patient are not well understood.
Because most patients with NVAMD receive fewer than
monthly injections based on PRN and treat-and-extend
dosing approaches,5 it would be desirable to identify during
initiation of therapy those treatment-naïve patients who will
beneﬁt most if they are given monthly anti-VEGF in-
jections. However, there are few data available to guide the
clinician in this regard, even from the primary data from the
VIEW studies. The design of the VIEW studies afforded us
the opportunity to study outcomes based on ﬂuid status. We
began by evaluating the ﬂuid status over time and treatment
effect on ﬂuid status. This analysis subsequently led us to
focus on the ﬂuid status in the initial phase of therapy. Data
from this on-treatment analysis have the potential to provide
valuable information to the clinician. Speciﬁcally, from
VIEW 1 and VIEW 2, we determined (1) the degree of retinal
ﬂuid ﬂuctuation, (2) the time to absence of retinal ﬂuid, and
(3) whether the presence of persistent retinal ﬂuid observed
after 3 initial monthly intravitreal injections, as seen on time-
domain OCT, predicted longer-term outcomes and visual
acuity, and whether these visual acuity changes depended on
the treatment regimen. We also assessed whether the visual
acuity outcomes observed throughout the study would differ
on the basis of ﬂuid type (subretinal or intraretinal). If so, this
information could help to inform the clinician about injection
frequency strategy in eyes with NVAMD.Methods
VIEW 1 and VIEW 2 Study Designs
The VIEW 1 and VIEW 2 studies were 2 similarly designed,
randomized, double-masked, active-controlled, multicenter, 96-
week, phase 3 trials comparing the efﬁcacy and safety of IAI
and ranibizumab in treatment-naïve eyes with NVAMD. The
design of the VIEW studies has been described.2,12 Each clinical
site’s respective institutional review board/ethics committee
approved the study. All patients provided written informed con-
sent. Participants were randomized in a 1:1:1:1 ratio to 1 of the
following 4 regimens for the ﬁrst 52 weeks: (1) 0.5 mg intravitreal
ranibizumab every 4 weeks (Rq4), (2) 2 mg IAI every 4 weeks
(2q4), (3) 0.5 mg IAI every 4 weeks, and (4) 2 mg IAI every 8
weeks (2q8) after 3 initial monthly injections. From week 52 to
week 96, patients were treated with the same dose as the ﬁrst 52
weeks at least every 12 weeks, with monthly evaluations for
additional injections.12 Analyses presented in this article were
limited to data through week 52 because the dosing regimen in
all treatment arms changed to PRN from week 52 to week 96,
and thus this period is not included in our analysis.
Outcome Measures
Independent masked readers at 2 central reading centers, Duke
Reading Center (VIEW 1) and Vienna Reading Center (VIEW 2),
determined the presence (termed “wet”) or absence (denoted “dry”)
of retinal ﬂuid. The OCT image grading was harmonized between
the Duke and Vienna OCT reading centers. This process included
conference calls and joint grading exercises on representativeimage samples to ensure that the same grading procedure was
followed at the 2 institutions.
Retinal ﬂuid was deﬁned as the presence of intraretinal (cystic)
ﬂuid or subretinal ﬂuid on time-domain OCT images at baseline
and then monthly through week 52. The time to a single absence
of retinal ﬂuid and sustained absence of retinal ﬂuid (ﬂuid absent
on 2 consecutive visits) was determined. Eyes that were not dry
by week 12 were then further evaluated. Because retinal ﬂuid can
ﬂuctuate depending on anti-VEGF treatment, we deﬁned an “early
persistent ﬂuid” group as one that had retinal ﬂuid as deﬁned
earlier on all initial 4 visits (baseline and weeks 4, 8, and 12). This
period included all 3 visits during the initial loading dose period
when all eyes were treated every 4 weeks, as well as 4 weeks after
the third treatment. Speciﬁc baseline characteristics were evaluated
to determine the inﬂuence on persistent ﬂuid status. The mean
change from baseline best-corrected visual acuity (BCVA), as
measured by Early Treatment Diabetic Retinopathy Study letters
over week 52, and the proportion of eyes gaining 15 letters and
losing 5 letters in eyes with early persistent ﬂuid were compared
with those without early persistent ﬂuid. In addition, we deter-
mined whether the ﬂuid type, intraretinal or subretinal, inﬂuenced
visual outcomes for those eyes with and those without early
persistent ﬂuid.
Statistical Analysis
Of the 2457 eyes randomized into the VIEW studies, 2412 pa-
tients received study medication and had a baseline and at least 1
postbaseline BCVA assessment (full analysis set). The 597 eyes
treated with 0.5 mg IAI every 4 weeks were not included in the
analysis because IAI 2 mg is the Food and Drug Admin-
istrationeapproved dose, and the only dose currently available to
clinicians in the United States. Thus, a total of 1815 eyes (Rq4,
n ¼ 595; 2q4, n ¼ 613; and 2q8, n ¼ 607) were included in these
analyses. There were 91 eyes (34 eyes in the Rq4 group, 29 eyes
in the 2q4 group, and 28 eyes in the 2q8 group) with missing
observations in at least one visit during baseline to week 12. These
eyes were classiﬁed as wet if the preceding and the following
visits were classiﬁed as wet.
Time to absence of retinal ﬂuid was evaluated by the
KaplaneMeier method and a proportional hazard analysis. These
approaches provided a means to estimate the cumulative incidence
and accounts for eyes that did not have complete follow-up. The
log-rank test was used to test the difference between the cumula-
tive incidence curves of the treatment groups. The relative risks (or
relative hazards) comparing the various IAI treatment groups with
the Rq4 group were estimated by the proportional hazards anal-
ysis. Time at risk for each patient is the minimum from the time at
randomization to the ﬁrst of any of the following: (1) the date of
discontinuation, (2) the ﬁrst episode of dryness, or (3) the end of
the study. Time at risk is expressed as person-years at risk, and the
rate is the number of events/person-years at risk. The relative risk
(or hazard) is determined as the ratio of the rate in the ranibizumab
group to the rate in the IAI group. The relative risk analyses were
stratiﬁed by study (VIEW 1 vs. VIEW 2). Only within-stratum
analyses contributed to the overall relative risks. Logistic regres-
sion was used to determine baseline factors that were useful to
predict eyes that had persistent retinal ﬂuid. Repeated-measures
methodology was used to evaluate the differences in the means
of groups deﬁned by on-treatment variables. On-treatment vari-
ables are those that are evaluated after randomization. Analysis of
covariance was used to assess differences in BCVA between the
treatment groups. The covariates used in the model are baseline
characteristics listed in Table 1. Least-squares means are reported
and implicitly corrected for sample size imbalances among the
treatment groups.1857
Table 1. Baseline Characteristics of Patients with and without Persistent Retinal Fluid* by Treatment Groups
Rq4 (N [ 595) IAI 2q4 (N [ 613) IAI 2q8 (N [ 607)
Not Persistent Persistent Not Persistent Persistent Not Persistent Persistent
Patients (n) 420 175 498 115 484 123
BCVA (ETDRS letters), mean  SD 53.6 (13.4) 54.5 (13.5) 54.1 (13.8) 53.3 (12.7) 53.9 (13.4) 52.4 (13.7)
CST (mm), mean  SD 289.8 (122.1) 311.0 (123.5) 292.1 (127.3) 325.9 (118.9) 292.8 (126.4) 357.2 (149.3)
CNV lesion size, n (%)
10.16 mm2 324 (77.1) 123 (70.3) 373 (74.9) 82 (71.3) 349 (72.1) 99 (80.5)
>10.16 mm2 91 (21.7) 51 (29.1) 124 (24.9) 31 (27.0) 134 (27.7) 23 (18.7)
Missing 5 (1.2) 1 (0.6) 1 (0.2) 2 (1.7) 1 (0.2) 1 (0.8)
CNV lesion type, n (%)
Occult 163 (38.8) 68 (38.9) 194 (39.0) 39 (33.9) 191 (39.5) 38 (30.9)
MC 145 (34.5) 60 (34.3) 187 (37.6) 30 (26.1) 180 (37.2) 36 (29.3)
PC 106 (25.2) 46 (26.3) 115 (23.1) 44 (38.3) 111 (22.9) 48 (39.0)
Missing 6 (1.4) 1 (0.6) 2 (0.4) 2 (1.7) 2 (0.4) 1 (0.8)
Full analysis set.
BCVA ¼ best-corrected visual acuity; CST ¼ central subﬁeld thickness; ETDRS ¼ Early Treatment Diabetic Retinopathy Study; IAI ¼ intravitreal
aﬂibercept injection; MC ¼ minimally classic; PC ¼ predominantly classic; Rq4 ¼ 0.5 mg intravitreal ranibizumab every 4 weeks; SD ¼ standard deviation;
2q4 ¼ 2 mg every 4 weeks; 2q8 ¼ 2 mg every 8 weeks.
*Persistent ﬂuid was deﬁned as the presence of intraretinal or subretinal ﬂuid on all initial 4 visits (baseline and weeks 4, 8, and 12).
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Retinal Fluid Status over Time
Retinal ﬂuid status based on the presence or absence of retinal ﬂuid
was ﬁrst determined at each study visit for each treatment group.
During the 52 weeks of follow-up, the retinal ﬂuid status as deﬁned
earlier ﬂuctuated in all treatment groups, although greater ﬂuctu-
ation over time was noted in the 2q8 group. Speciﬁcally, the
average proportions of visits without retinal ﬂuid were 57.4%,
75.1%, and 57.9% in the Rq4, 2q4, and 2q8 groups, respectively.
Figure 1 shows the proportion of eyes without retinal ﬂuid by visit
and treatment assignment.
Time to Absence of Retinal Fluid
Time to retinal ﬂuid absence (“dryness”) was compared among the
3 treatment groups (Fig 2A). By week 52, there were 512, 571, and
548 study eyes with retinal ﬂuid absent on at least 1 study visit,Figure 1. Proportion of patients without retinal ﬂuid over 52 weeks of study. IA
every 4 weeks; 2q4 ¼ 2 mg every 4 weeks; 2q8 ¼ 2 mg every 8 weeks after 3
1858with resultant cumulative incidences of 86.9%, 93.9%, and
91.9% in the Rq4, 2q4, and 2q8 groups, respectively. The IAI
groups were more likely than the Rq4 group to have an episode
of absent retinal ﬂuid: 1.5 (2q4) and 1.4 (2q8) times,
respectively. The overall rates (calculated as the number of
events per 100 person-years at risk of dryness) between the 2q4
and 2q8 groups were similar. The separation between the IAI and
Rq4 groups was seen early and was maintained through 52 weeks.
As expected, the 2q4 and 2q8 cumulative incidence curves were
almost identical until week 16. Thereafter, there was a slight sep-
aration between the 2 IAI groups. In both the 2q4 and 2q8 groups,
more than 50% of the study eyes had the ﬁrst episode of retinal
ﬂuid absence by week 4. At week 12, more than 75% of the eyes
treated with 2q4 or 2q8 were dry on at least 1 visit. The 75%
cumulative incidence of a dry retina on at least 1 visit for eyes
treated with Rq4 was reached at week 20.
The proportion of eyes with sustained dryness, deﬁned as absent
ﬂuid on at least 2 consecutive visits, and the time to sustained dryness
were then assessed for each of the 3 treatment groups (Fig 2B). ThereI ¼ intravitreal aﬂibercept injection; Rq4 ¼ 0.5 mg intravitreal ranibizumab
initial monthly injections.
Figure 2. Cumulative incidence of (A) single and (B) sustained absence of retinal ﬂuid. Sustained absence refers to absent retinal ﬂuid on 2 or more
consecutive visits. Full analysis set. CI ¼ conﬁdence interval; IAI ¼ intravitreal aﬂibercept injection; PYR ¼ person-years; R 0.5q4 ¼ 0.5 mg intravitreal
ranibizumab every 4 weeks; 2q4 ¼ 2 mg every 4 weeks; 2q8 ¼ 2 mg every 8 weeks.
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more consecutive study visits by week 52 that resulted in
cumulative incidences of 73.7%, 84.8%, and 73.8% in the Rq4,
2q4, and 2q8 groups, respectively. The rates of the events are
provided in the table within Fig 2B. On the basis of the relative
hazard ratio for sustained dryness, eyes treated 2q4 were
approximately 1.5 times more likely than those treated Rq4 and
2q8 to achieve sustained dryness. During the ﬁrst 12 weeks, the
cumulative incidence of sustained dryness in the 2q4 and 2q8
groups was similar, but from week 16 onward, the cumulative
incidence of sustained dryness in the 2q8 group was lower than
that observed in the 2q4 group. The separation for the cumulative
incidence curves between 2q4 and Rq4 was seen early, at
approximately week 4. The 50th percentile for the cumulative
incidence of sustained dryness was achieved at week 8 in both of
the IAI groups. The 75th percentile was achieved at week 24 for
the 2q4 group but was never achieved for the 2q8 or Rq4 groups.
Evaluation of Early Persistent Fluid
We next determined how frequently retinal ﬂuid persisted over
each of the ﬁrst 4 study visits (including baseline) through week12 (termed “early persistent ﬂuid”) and whether the speciﬁc anti-
VEGF treatment affected ﬂuid persistence. For this analysis, eyes
were determined to have early persistent ﬂuid if the presence of
ﬂuid was conﬁrmed at all initial 4 visits: baseline, week 4, week 8,
and week 12. Those that did not meet this criterion were deter-
mined not to have early persistent ﬂuid. Most eyes (1402 [77.2%])
did not have early persistent ﬂuid over the ﬁrst 4 visits through
week 12: 420 eyes (70.6%), 498 eyes (81.2%), and 484 eyes
(79.7%) in the Rq4, 2q4, and 2q8 treatment groups, respectively.
Overall, 413 eyes (22.8%) had early persistent retinal ﬂuid during
the ﬁrst 4 visits. The proportion of eyes with early persistent ﬂuid
was similar in the IAI arms (2q4:18.8%, 115/613; 2q8: 20.3%,
123/607; combined 19.5%, 238/1220), as expected since both
were dosed monthly during the loading phase, while eyes treated
with Rq4 were 51% more likely (95% conﬁdence interval [CI]:
27%, 78%) to have early persistent ﬂuid (Rq4: 29.4%; 175/595).
Eyes with and without early persistent ﬂuid through week 12 had
similar baseline visual acuity, lesion size, and lesion type across
treatment groups (Table 1). However, eyes with early persistent
ﬂuid had greater baseline central subﬁeld thickness on OCT
across treatment groups compared with eyes without early
persistent ﬂuid.1859
Figure 3. Least square mean change in best-corrected visual acuity (BCVA) from baseline through week 52 in eyes (A) without and (B) with persistent
retinal ﬂuid through week 12. ETDRS ¼ Early Treatment Diabetic Retinopathy Study; IAI ¼ intravitreal aﬂibercept injection; Rq4 ¼ 0.5 mg intravitreal
ranibizumab every 4 weeks; 2q4 ¼ 2 mg every 4 weeks; 2q8 ¼ 2 mg every 8 weeks.
Ophthalmology Volume 123, Number 9, September 2016Relationships between Early Persistent Fluid
and Visual Acuity
For eyes without early persistent retinal ﬂuid (from baseline
through week 12), there were no differences among the treatment
groups in mean BCVA change from baseline over the interval
beginning at week 16 and spanning through week 52 (Fig 3A). An
examination of the means and error bars at each visit suggests no
differences between the treatment groups at any visit.
In contrast, in eyes with early persistent ﬂuid from baseline
through week 12, the mean BCVA gains from baseline over the
interval spanning weeks 16 to 52 were observed as early as week
16 for the 2q4 group and were consistently greater than those for
the 2q8 and Rq4 groups. An analysis of covariance using cova-
riates from Table 1 conﬁrms and quantiﬁes these suggestions at
week 52. A test of the equality of the means among the
treatment groups was rejected (P ¼ 0.006). Pairwise treatment
group comparisons yield the following: 2q4 versus 2q8 and 2q4
versus Rq4 are P ¼ 0.006 and P ¼ 0.049, respectively, and the
P value for Rq4 versus 2Q8 is 0.294. The adjusted mean1860changes from baseline at week 52 were 11.7, 8.5, and 7.5 letters
for the 2q4, Rq4, and 2q8 groups, respectively (Fig 4). These
mean changes correspond to difference of 3.2 letters for 2q4
versus Rq4, 4.2 letters for 2q4 versus 2q8 and 1.0 letters for Rq4
versus 2q8.
At week 52, the percentages of study eyes that gained 15
letters were similar among the 3 study groups: 33.7% (95% CI,
26.5e41.0), 35.2% (95% CI, 26.2e44.2), and 31.5% (95% CI,
22.9e40.2) for Rq4, 2q4, and 2q8, respectively (Fig 5A).
However, a lower percentage of eyes in the 2q4 group lost 5
letters compared with eyes in the Rq4 and 2q8 groups (6.5%
[95% CI, 1.8e11.1] vs. 16.6% [95% CI, 10.9e22.3] and 16.2%
[95% CI, 9.4e23.1]) (Fig 5B).
The described analysis in eyes with early persistent ﬂuid
through week 12 was repeated separately for persistent ﬂuid sub-
types: 52 eyes (8.7%), 43 eyes (7%), and 45 eyes (7.4%) with early
persistent intraretinal ﬂuid, and 113 eyes (19.0%), 57 eyes (9.3%),
and 76 eyes (12.5%) with early persistent subretinal ﬂuid in the
Rq4, 2q4, and 2q8 treatment groups, respectively. However, the
numbers of eyes available for these analyses were small. In
Figure 4. Adjusted mean changes in best-corrected visual acuity (BCVA)
from baseline at week 52 in eyes with persistent retinal, intraretinal, or
subretinal ﬂuid through week 12. Rq4 ¼ 0.5 mg intravitreal ranibizumab
every 4 weeks; 2q4 ¼ 2 mg every 4 weeks; 2q8 ¼ 2 mg every 8 weeks.
Figure 5. Proportion (95% conﬁdence interval) of eyes with persistent
retinal, intraretinal, or subretinal ﬂuid through week 12 that (A) gained
15 letters or (B) lost 5 letters from baseline at week 52. Rq4 ¼ 0.5 mg
intravitreal ranibizumab every 4 weeks; 2q4 ¼ 2 mg every 4 weeks; 2q8 ¼ 2
mg every 8 weeks.
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52 was similar regardless of whether the early persistent ﬂuid was
intraretinal or subretinal.
At week 52, the percentages of study eyes with early persistent
intraretinal ﬂuid that gained 15 letters were 30.0% (95% CI,
17.3e42.7), 31.0% (95% CI, 17.0e44.9), and 29.3% (95% CI,
15.3e43.2) in the Rq4, 2q4, and 2q8 treatment groups, respec-
tively (Fig 5A), whereas the percentages of eyes with early
persistent intraretinal ﬂuid that lost 5 letters were 16.0% (95%
CI, 5.8e26.2), 4.8% (95% CI, 0.0e11.2), and 22% (95% CI,
9.3e34.6), respectively (Fig 5B). In these eyes, at week 52, the
mean changes in BCVA from baseline were 6.4, 11.8, and 7.3
letters for Rq4, 2q4, and 2q8, respectively (Fig 6A).
More eyes with persistent subretinal ﬂuid treated with 2q4 gained
15 letters, and fewer lost5 letters of visual acuity than eyes treated
with Rq4 or 2q8 (Figs 5A and B). The proportions of eyes that gained
15 letters were 34.9% (95% CI, 25.8e44.0), 40.7% (95% CI,
27.6e53.9), and 25.8% (95% CI, 15.2e36.3), whereas the
proportions of eyes that lost 5 letters were 20.8% (95% CI,
13.0e28.5), 9.3% (95% CI, 1.5e17.0), and 15.2% (95% CI,
6.5e23.8) for Rq4, 2q4, and 2q8, respectively (Fig 5A and B). In
this group, the mean BCVA changes from baseline at week 52 were
8.3, 11.9, and 5.5 letters for Rq4, 2q4, and 2q8, respectively (Fig 6B).Discussion
To our knowledge, this report is the ﬁrst to evaluate the
proportion of eyes with early persistent ﬂuid after 3 anti-
VEGF “loading” injections and the effect of this ﬂuid on
subsequent visual acuity. In the pivotal phase 3 VIEW 1 and
VIEW 2 trials, overall, 2 mg IAI monthly and every 2
months (after 3 initial injections) were clinically equivalent
to ranibizumab monthly for the primary end point of mean
change in visual acuity from baseline at week 52 in patients
with NVAMD.2 However, ﬂuid status, particularly early
persistent ﬂuid, and its effect on visual outcomes were not
explored in the primary analyses. Likewise, other large
randomized anti-VEGF treatment trials, such as CATT
and Inhibition of VEGF in Age-related choroidal Neo-
vasularisation (IVAN), showed that ranibizumab and bev-
acizumab had similar visual acuity outcomes when the
totality of the data were considered, but they did not report
the proportion of eyes with persistent ﬂuid or the effect of
persistent ﬂuid on subsequent visual acuity.3,6 Our datashow that although the proportion of eyes with retinal or
subretinal ﬂuid ﬂuctuated during the ﬁrst year of therapy,
most eyes did not have early persistent ﬂuid, and for this
group of eyes, IAI given every 4 or 8 weeks, or ranibizumab
every 4 weeks, had a similar effect on visual acuity,
consistent with the overall results reported in the VIEW 1
and VIEW 2 studies.2 However, when early persistent ﬂuid
was present after the initial 3 injections (a ﬁnding present in
approximately 20% of eyes initially treated with IAI and in
30% of eyes with Rq4), there may be a beneﬁt to monthly
IAI compared with the other regimens as demonstrated by
a higher proportion of dry retinas, a greater visual acuity
improvement, and a smaller proportion with visual acuity
loss in eyes treated with 2q4 compared with eyes treated
with Rq4 or 2q8 at week 52.
The reason for better visual acuity outcomes in the IAI
2q4 treatment group among eyes with persistent ﬂuid is
unknown. In the CATT, continuous monthly injections of
bevacizumab and ranibizumab resulted in slightly better
BCVA than PRN injections at years 1 and 2.3,10 We
hypothesize that treatment-naïve eyes, in which the ﬂuid
persists after initial treatment, may be less sensitive to the1861
Figure 6. Mean change in best-corrected visual acuity (BCVA) from baseline through week 52 in eyes with (A) persistent intraretinal ﬂuid or (B) persistent
subretinal ﬂuid through week 12. IAI ¼ intravitreal aﬂibercept injection; ETDRS ¼ Early Treatment Diabetic Retinopathy Study; Rq4 ¼ 0.5 mg intravitreal
ranibizumab every 4 weeks; 2q4 ¼ 2 mg every 4 weeks; 2q8 ¼ 2 mg every 8 weeks.
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anti-VEGF treatment to avoid the adverse effects of ﬂuid on
photoreceptors and other neurosensory retinal structures.
We were unable to assess the effect of early persistent
ﬂuid on retinal microanatomy because lower-resolution
time-domain OCT was used in this study. However, in
ongoing or future anti-VEGF NVAMD treatment trials in
which spectral-domain OCT is used, it will be of interest to
evaluate the effect of persistent ﬂuid on inner and outer
retinal structures, such as the ganglion cell complex, inner
nuclear layer, external limiting membrane, ellipsoid zone,
and photoreceptor outer segments.
In previous anti-VEGF NVAMD interventional studies,
the speciﬁc type of ﬂuid had differing effects on visual
acuity. Indeed, in the CATT, eyes with intraretinal ﬂuid had
worse visual acuity, whereas eyes with subretinal ﬂuid had
better visual acuity than those without these types of ﬂuid.3
These data led us to speculate that the effects of anti-VEGF1862therapy in eyes with early persistent ﬂuid after initial
loading doses might differ depending on whether the ﬂuid
was intraretinal ﬂuid or subretinal ﬂuid. Of note, we found
that the type of ﬂuid was not important in this regard; eyes
with early persistent intraretinal ﬂuid beneﬁted from anti-
VEGF therapy to the same degree as those with subretinal
ﬂuid, and eyes with early persistent ﬂuid, regardless of ﬂuid
type, beneﬁted more from IAI 2q4 compared with IAI 2q8
or monthly ranibizumab. In a different analysis of VIEW 1
and VIEW 2 data, eyes with baseline intraretinal ﬂuid had
worse visual acuity at week 52 than those without intra-
retinal ﬂuid.13 The CATT data and those reported by
Waldstein et al13 are not inconsistent with the ﬁndings in
the present report because the study methodology and
main end points were different. In the CATT, the subtype
of ﬂuid was correlated with visual acuity at each study
visit, and in the study by Waldstein et al,13 the analysis
was conducted to determine how the baseline morphology
Jaffe et al  Visual Acuity in NVAMD with Persistent Fluidcharacteristics (that included intraretinal ﬂuid) affected the
week 52 visual acuity. In contrast, in this report, the goal
was to determine the effect of drug type and treatment
frequency in eyes with or without persistent ﬂuid over the
ﬁrst 4 visits on subsequent visual acuity outcomes.
We found that persistent subretinal ﬂuid did not prevent
15 letter gains in any of the 3 treatment groups, but was
associated with a 5 letter loss in the Rq4 and 2q 8 cohorts.
The reason for this ﬁnding is unclear. Regardless, the overlap
within the wide CIs across treatment groups with such a small
sample size in this subgroup makes it difﬁcult to deﬁnitively
determine whether these results are clinically meaningful.
When there was early persistent ﬂuid, eyes treated with
monthly aﬂibercept had better visual acuity at week 52 than
those treated with aﬂibercept less frequently or those treated
with ranibizumab. The differences in visual acuity among the
treatment groupswere seen early, atweek16, theﬁrst visit after
the deﬁned period of persistent ﬂuid, and were maintained
through week 52. This observation is consistent with the
hypothesis that visual acuity differences among treatment
groups at week 52 reﬂect ﬂuid status during the initial early
treatment period.
It might be tempting to speculate that elimination of
subretinal ﬂuid after this initial early period would have a
beneﬁcial effect on visual acuity. However, this study was
not designed to determine the effect of subretinal ﬂuid res-
olution on visual acuity after the ﬁrst 12 weeks. Further-
more, although the CATT, VIEW 1, and VIEW 2 have
recently shown that subretinal ﬂuid did not adversely affect
visual acuity at individual study visits,4,14 those studies also
were not designed to study the effect of subretinal ﬂuid
resolution on visual acuity. Future studies designed to
determine how aggressively to treat subretinal ﬂuid when it
is present after the ﬁrst 12 weeks are warranted and would
help to answer this question. Overall, eyes treated with both
monthly and every 2 months IAI were less likely to have
persistent ﬂuid through week 12 and achieved a dry retina
earlier and in a higher proportion of patients compared with
ranibizumab. Furthermore, in eyes treated with monthly IAI,
a dry retina was more likely to be sustained than in those
treated with IAI every 2 months or ranibizumab every
month. Together, these data indicate that IAI, at the doses
used in this study, has a more pronounced antipermeability
effect than ranibizumab in eyes with NVAMD. This anti-
permeability effect has potential clinical implications
because eyes treated with IAI were less likely to have
persistent ﬂuid through week 12; therefore, theoretically, in
these patients without persistent ﬂuid, a higher percentage of
IAI-treated eyes could be managed with therapy every 2
months when compared with those treated with ranibizu-
mab. As described next, this hypothesis would need to be
tested in a prospective trial.
This study has several strengths. Data were obtained from 2
large, randomized, masked trials. Accordingly, there was
adequate power to determine the effects of persistent ﬂuid on
visual acuity. Furthermore, bias was minimized during data
collection because trained readers masked to treatment group
analyzed images at 2 independent reading centers, andmasked
visual acuity examiners performed the visual acuity
measurements.Study Limitations
Our analysis has limitations. The data were analyzed post
hoc, and the original studies were not designed to determine,
in a prospective manner, whether eyes with early persistent
ﬂuid after IAI treatment should be maintained on monthly
IAI or whether eyes with persistent ﬂuid after ranibizumab
should be switched to monthly IAI. Adjustments for mul-
tiplicity were not made because these analyses were not
prespeciﬁed. Thus, there is potential for type I and II errors.
Furthermore, time-domain OCT was used to deﬁne persis-
tent ﬂuid, and results could have varied if higher-resolution
spectral-domain systems had been used. This analysis is
limited to evaluation of the ﬁxed-dosing regimens through
week 52. We cannot comment on the duration of monthly
IAI treatment that would be needed for eyes with early
persistent ﬂuid to achieve maximal visual gains, nor do
these results indicate how patients with early persistent ﬂuid
may have beneﬁtted from an individualized “treat-and-
extend” strategy with either IAI or ranibizumab or a PRN
strategy, such as that used in the CATT.3,9,10
Nonetheless, our data generate useful hypotheses
regarding treatment strategies when ﬂuid persists after initial
monthly anti-VEGF loading doses that could be tested in
future trials. For example, our data suggest that patients with
persistent ﬂuid after 3 initial monthly anti-VEGF injections
may beneﬁt from continued treatment with monthly IAI
2q4. Future interventional NVAMD studies could test this
hypothesis. To further inform a persistent ﬂuid management
strategy, it would be useful to conduct a trial to assess the
effect on visual acuity of a treat-and-extend, PRN, or PRN
individualized dosing strategy and the effect of switching to
IAI 2q4 in eyes with persistent ﬂuid after initial monthly
injections with another anti-VEGF agent.
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